Engineered Bacteria Use Quorum Sensing to Eat Tumors Without Escaping Into the Blood

Solid tumors create their own problem. As a mass of cancer cells outgrows its blood supply, the interior becomes starved of oxygen - a condition called hypoxia. That dead center, packed with necrotic tissue and devoid of the oxygen that most living things require, is ordinarily an obstacle for therapies that rely on blood circulation to reach their target. A research team at the University of Waterloo has been working to turn that obstacle into an advantage.

The approach exploits a bacterium called Clostridium sporogenes, a soil organism that not only tolerates oxygen-free environments but requires them. Normal oxygen levels are lethal to it. The anaerobic core of a solid tumor is, for this organism, ideal territory - nutrient-rich and oxygen-free. When spores of C. sporogenes are introduced near a tumor, they can germinate inside that core and proliferate, consuming the tissue from within.

The edge problem

The core of a tumor is not the only part that needs to be destroyed. The outer region - where the tumor is still oxygenated and active - contains the cancer cells most likely to survive, metastasize, and drive disease progression. When C. sporogenes reaches the periphery of a tumor, it encounters low but non-zero oxygen levels, and it dies. The mission goes unfinished.

"Bacteria spores enter the tumour, finding an environment where there are lots of nutrients and no oxygen, which this organism prefers, and so it starts eating those nutrients and growing in size," said Dr. Marc Aucoin, a chemical engineering professor at Waterloo. "So, we are now colonizing that central space, and the bacterium is essentially ridding the body of the tumour."

The challenge the Waterloo team set out to solve: how to extend bacterial survival to the tumor's outer layers without creating an organism that could grow in oxygen-rich locations like the bloodstream - a scenario with obvious and dangerous consequences.

Building in a timing switch

The solution involved two separate genetic modifications working in sequence. First, the researchers added a gene from a related bacterium that confers greater tolerance for oxygen, allowing the modified C. sporogenes to survive at the tumor periphery long enough to do its work. Second, they designed a control system using quorum sensing to regulate when this gene activates.

Quorum sensing is a natural form of bacterial communication. Bacteria release chemical signal molecules into their surroundings, and the concentration of those molecules rises as the local bacterial population grows. When the signal crosses a threshold, it triggers a coordinated behavioral change across the group. In natural contexts, bacteria use this to synchronize activities like biofilm formation or toxin production.

The Waterloo team engineered the oxygen-tolerance gene to activate only when the quorum sensing signal reaches a concentration that indicates the bacteria have already colonized the anaerobic tumor interior in substantial numbers. Only then does the switch flip, allowing the modified organisms to survive at the edges.

"Using synthetic biology, we built something like an electrical circuit, but instead of wires we used pieces of DNA," said Dr. Brian Ingalls, a professor of applied mathematics at Waterloo. "Each piece has its job. When assembled correctly, they form a system that works in a predictable way."

Two studies, one toward combination

The team published two separate studies covering the two components. The first demonstrated that C. sporogenes could be modified to tolerate oxygen. The second tested the quorum sensing control system by wiring it to produce a green fluorescent protein as a visible marker - confirming that the gene switch activates at the right time and in the right conditions.

The next step is combining both modifications in a single bacterium and testing it in pre-clinical tumor models. That work would represent the first full test of the complete system - oxygen-tolerant bacteria with a built-in safety switch that limits that tolerance to the tumor environment.

What the research has not yet done

Neither study has tested the combined system in animals, and no human trials are on the horizon in the near term. The gap between a functional genetic circuit demonstrated in bacterial cultures and a therapy proven safe and effective in clinical settings involves years of systematic testing. Important unknowns include whether the quorum sensing threshold is reliably calibrated across different tumor types and sizes, how the modified bacteria interact with the immune system, and whether any bacterial products could be harmful to surrounding healthy tissue.

Bacteria-based cancer therapies have been studied for decades. The concept dates to William Coley's observation in the late 19th century that bacterial infections sometimes correlated with tumor regression. Modern approaches, while far more mechanistically sophisticated, still face the fundamental challenge of controlling biological activity precisely enough to be both effective and safe in a clinical setting.

The project grew from the doctoral work of Bahram Zargar, supervised by Ingalls and Dr. Pu Chen, and the team includes Dr. Sara Sadr, a former Waterloo doctoral student. Waterloo partnered with the Center for Research on Environmental Microbiology (CREM Co Labs), a Toronto company co-founded by Dr. Zargar, on the research.